<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="159868">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02050594</url>
  </required_header>
  <id_info>
    <org_study_id>CA184-366</org_study_id>
    <nct_id>NCT02050594</nct_id>
  </id_info>
  <brief_title>Ipilimumab 12-month Intensive Pharmacovigilance Protocol</brief_title>
  <official_title>Ipilimumab 12-month Intensive Pharmacovigilance Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>JSS Medical Research Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <authority>Venezuela: CENAVIF (National Center for Pharmacovigilance)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the protocol is to identify and describe observed adverse events
      (AEs) while on treatment with Ipilimumab for advanced melanoma in Venezuela during the study
      period
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Descriptive statistics of observed adverse events (AEs) while on treatment with Ipilimumab for advanced melanoma in Venezuela</measure>
    <time_frame>Up to 12 months of treatment</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Melanoma patients on Ipilimumab</arm_group_label>
    <description>All unresectable, recurrent or metastatic melanoma patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <arm_group_label>Melanoma patients on Ipilimumab</arm_group_label>
    <other_name>Yervoy</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Bristol Myers de Venezuela S.A.C. has in place a Customer Model registry, which tracks
        every Ipilimumab prescription in Venezuela. Therefore, any oncologist who treats a patient
        with Ipilimumab will be identified by BMS. Use of this registry will ensure all patients
        who are infused with Ipilimumab are included in this study
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com.

        Inclusion Criteria:

          -  Age of 18 years or older on date of first dose of Ipilimumab

          -  Subjects who received at least 1 dose of Ipilimumab for the treatment of
             unresectable, recurrent or metastatic melanoma in Venezuela

        Exclusion Criteria:

          -  Subjects who received Ipilimumab as part of a clinical trial

          -  Subjects who received Ipilimumab for any indication other than local approval (ie,
             unresectable or metastatic melanoma)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>For Site information please email:</last_name>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of email MUST contain NCT# &amp; Site#. Only trial site that are recruiting have contact information at this time</last_name>
  </overall_contact_backup>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trials Disclosure</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 29, 2014</lastchanged_date>
  <firstreceived_date>January 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
